Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CORCEPT THERAPEUTICS INCCORT · Entity 2620 | Director · Chief Executive Officer | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CORCEPT THERAPEUTICS INC
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectJoseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 | 2,565,489 |
Last balance in matching sequence
After 2026-06-01 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-29 · Gift · Disposed 300,000 · Balance 2,578,326 F1: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Row 4 · 2026-06-01 · Sale · Disposed 12,837 · Balance 2,565,489 F6: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. F1: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectJoseph K. Belanoff 2026 Grantor Retained Annuity Trust | 150,000 |
Reported balance
After 2026-05-29 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-29 · Gift · Acquired 150,000 · Balance 150,000 F2: Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust. F3: Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee. |
| Common StockSEC Table I · non-derivative | IndirectKatherine A. Blenko 2026 Grantor Retained Annuity Trust | 150,000 |
Reported balance
After 2026-05-29 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-05-29 · Gift · Acquired 150,000 · Balance 150,000 F4: Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust. F5: Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
F2: Transfer of shares without consideration to the Joseph K. Belanoff 2026 Grantor Retained Annuity Trust.
F3: Shares are held by Joseph K. Belanoff 2026 Grantor Retained Annuity Trust, of which the Reporting Person is the trustee.
F4: Transfer of shares without consideration to the Katherine A. Blenko 2026 Grantor Retained Annuity Trust.
F5: Shares are held by Katherine A. Blenko 2026 Grantor Retained Annuity Trust, of which the spouse of the Reporting Person is the trustee.
F6: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 279,908 | $26.27 | $7,352,007.55 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02 Disclosed balance after: 2,538,218 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2022, as amended. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $26.21 to $26.65. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. F5 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 451,189 | $26.21 | $11,825,663.69 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,811 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on July 6, 2022. The options subject to the net exercise were to expire on January 30, 2023. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:20 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 800,000 | $2.08 | $1,664,000.00 |
DisclosureSEC source: 0000899243-22-025827 · doc4.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2022 Filed Feb 14, 2025 21:40 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | OtherCommon Stock | 348,811 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-021329 · ownership.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 Disclosed balance after: 2,831,918 F1 · kind: Transfer of shares without consideration to the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02. F2 · ownership.nature: Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. F3 · ownership.nature: Due to an administrative error, prior reporting of the name of this trust has been corrected. The exact name of the trust, "Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02" was mistakenly identified as the "Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 01/29/02". Read SEC document |
| July 06, 2022 Filed Feb 14, 2025 21:40 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GiftCommon Stock | 348,811 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-021329 · ownership.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,417 Read SEC document |
| February 02, 2022 Filed Feb 11, 2022 23:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $19.26 | $0.00 |
DisclosureSEC source: 0000899243-22-005945 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 2, 2022, so that the total number of shares subject to this option becomes fully vested and exercisable on February 2, 2026. Read SEC document |
| February 05, 2021 Filed Feb 8, 2021 22:19 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $29.41 | $0.00 |
DisclosureSEC source: 0000899243-21-005187 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2031-02-04 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 5, 2021, so that the total number of shares subject to this option becomes fully vested and exercisable on February 5, 2025. Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 02:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0000899243-21-003420 · doc4.xml · derivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 800,000 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 02:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 481,088 | $28.06 | $13,499,329.28 |
DisclosureSEC source: 0000899243-21-003420 · doc4.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,818,126 F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on January 22, 2021. The options subject to the net exercise were to expire on May 19, 2021. Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 02:33 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 800,000 | $4.42 | $3,536,000.00 |
DisclosureSEC source: 0000899243-21-003420 · doc4.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,299,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 23:54 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Disposition to issuerCommon Stock | 20,338 | $13.54 | $275,376.52 |
DisclosureSEC source: 0000899243-20-006342 · doc4.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,499,214 F1 · kind: These shares were sold so the Reporting Person could satisfy his remaining tax liability arising from a net (cashless) exercise of stock options that occurred in 2019. The date of the net exercise was March 20, 2019. The options subject to the net exercise were to expire on March 26, 2019. Read SEC document |
| February 07, 2020 Filed Feb 11, 2020 22:13 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000899243-20-004044 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2030-02-06 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2020, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2024. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 19:01 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 782,885 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000899243-19-008664 · doc4.xml · derivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 782,885 shares Expires 2019-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 19:01 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Tax withholdingCommon Stock | 427,528 | $11.93 | $5,100,409.04 |
DisclosureSEC source: 0000899243-19-008664 · doc4.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,519,552 F1 · kind: The shares were withheld at the election of the Reporting Person as payment for the purchased shares and to satisfy tax withholding obligations in connection with the purchase of the shares. Read SEC document |
| March 20, 2019 Filed Mar 21, 2019 19:01 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 782,885 | $1.19 | $931,633.15 |
DisclosureSEC source: 0000899243-19-008664 · doc4.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,947,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2019 Filed Feb 13, 2019 02:38 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 475,000 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0000899243-19-003380 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 8, 2019, so that the total number of shares subject to this option becomes fully vested and exercisable on February 8, 2023. Read SEC document |
| December 12, 2018 Filed Dec 15, 2018 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 217,115 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000899243-18-031128 · doc4.xml · derivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,885 Underlying: Common Stock · 217,115 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 12, 2018 Filed Dec 15, 2018 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 217,115 | $19.01 | $4,126,509.40 |
DisclosureSEC source: 0000899243-18-031128 · doc4.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164,195 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $18.75 to $19.48 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| December 12, 2018 Filed Dec 15, 2018 00:50 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 217,115 | $1.19 | $258,366.85 |
DisclosureSEC source: 0000899243-18-031128 · doc4.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,381,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2018 Filed Feb 13, 2019 02:41 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 217,115 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0000899243-19-003383 · doc4a.xml · derivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,885 Underlying: Common Stock · 217,115 shares Expires 2019-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. F3 · derivative.expiration_date: The transactions described herein were originally reported on a Form 4 filed on December 14, 2018. This Form 4 is hereby being amended to correct the stock option exercise date and it does not describe any additional transactions. Read SEC document |
| December 12, 2018 Filed Feb 13, 2019 02:41 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 217,115 | $19.01 | $4,126,509.40 |
DisclosureSEC source: 0000899243-19-003383 · doc4a.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164,195 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $18.75 to $19.48 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. Read SEC document |
| December 12, 2018 Filed Feb 13, 2019 02:41 UTC Amendment | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 217,115 | $1.19 | $258,366.85 |
DisclosureSEC source: 0000899243-19-003383 · doc4a.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,381,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2018 Filed Feb 10, 2018 01:15 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 475,000 | $0.00 Strike: $16.52 | $0.00 |
DisclosureSEC source: 0000899243-18-003471 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,000 Underlying: Common Stock · 475,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 7, 2018, so that the total number of shares subject to this option becomes fully vested and exercisable on February 7, 2022. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 23:04 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000899243-17-004044 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2027-02-10 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 10, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 10, 2021. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 00:43 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000899243-16-033400 · doc4.xml · derivative · entry 6 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2017-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 00:43 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 200,000 | $9.10 | $1,820,300.00 |
DisclosureSEC source: 0000899243-16-033400 · doc4.xml · nonDerivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164,195 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.91 to $9.36 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 00:43 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 200,000 | $1.50 | $300,000.00 |
DisclosureSEC source: 0000899243-16-033400 · doc4.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,364,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:43 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000899243-16-033400 · doc4.xml · derivative · entry 5 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 300,000 shares Expires 2017-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:43 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 300,000 | $8.90 | $2,670,450.00 |
DisclosureSEC source: 0000899243-16-033400 · doc4.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164,195 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.86 to $9.039 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request. Read SEC document |
| November 10, 2016 Filed Nov 15, 2016 00:43 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 300,000 | $1.50 | $450,000.00 |
DisclosureSEC source: 0000899243-16-033400 · doc4.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,464,195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2016 Filed Nov 10, 2016 01:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 406,467 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000899243-16-033097 · doc4.xml · derivative · entry 6 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 406,467 shares Expires 2017-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 07, 2016 Filed Nov 10, 2016 01:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionStock Option (Right to Buy) · Derivative | 93,533 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000899243-16-033097 · doc4.xml · derivative · entry 5 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 906,467 Underlying: Common Stock · 93,533 shares Expires 2017-04-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 07, 2016 Filed Nov 10, 2016 01:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 406,467 | $8.32 | $3,383,593.89 |
DisclosureSEC source: 0000899243-16-033097 · doc4.xml · nonDerivative · entry 4 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164,195 F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.27 to $8.375 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request. Read SEC document |
| November 07, 2016 Filed Nov 10, 2016 01:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 406,467 | $1.50 | $609,700.50 |
DisclosureSEC source: 0000899243-16-033097 · doc4.xml · nonDerivative · entry 3 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,570,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2016 Filed Nov 10, 2016 01:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | SaleCommon Stock | 93,533 | $8.22 | $768,953.50 |
DisclosureSEC source: 0000899243-16-033097 · doc4.xml · nonDerivative · entry 2 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,164,195 F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $8.22 to $8.24 per share. Detailed information on the exact number of shares sold at each sale price can be obtained upon request. Read SEC document |
| November 07, 2016 Filed Nov 10, 2016 01:29 UTC | CORCEPT THERAPEUTICS INC CORT · Entity 2620 | Exercise / conversionCommon Stock | 93,533 | $1.50 | $140,299.50 |
DisclosureSEC source: 0000899243-16-033097 · doc4.xml · nonDerivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,257,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.